Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume 43, Issue 5, Pages 1103-1119
Publisher
Springer Science and Business Media LLC
Online
2022-02-25
DOI
10.1038/s41401-022-00880-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways
- (2021) Yanyan Wang et al. Cells
- THR‐ß agonism improves disease activity and metabolism independent of body weight in a mouse model of non‐alcoholic steatohepatitis and fibrosis
- (2021) Aimo Kannt et al. BRITISH JOURNAL OF PHARMACOLOGY
- A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis
- (2021) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
- (2021) Lulu Sun et al. Nature Reviews Gastroenterology & Hepatology
- An update on drug development for the treatment of nonalcoholic fatty liver disease – from ongoing clinical trials to future therapy
- (2021) Monika Rau et al. Expert Review of Clinical Pharmacology
- Bile Acid Profiles Are Distinct among Patients with Different Etiologies of Chronic Liver Disease
- (2021) Chao Sang et al. JOURNAL OF PROTEOME RESEARCH
- Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
- (2021) Oriol Juanola et al. International Journal of Environmental Research and Public Health
- Conjugated secondary 12α-hydroxylated bile acids promote liver fibrogenesis
- (2021) Guoxiang Xie et al. EBioMedicine
- FXR in liver physiology: Multiple faces to regulate liver metabolism
- (2021) Katrin Panzitt et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption
- (2021) Bethan L. Clifford et al. Cell Metabolism
- Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life
- (2021) Zobair M. Younossi et al. Clinical Gastroenterology and Hepatology
- Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus
- (2021) Youngae Jung et al. LIVER INTERNATIONAL
- Role of bile acids in inflammatory liver diseases
- (2021) Ioannis Evangelakos et al. Seminars in Immunopathology
- A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes
- (2021) Stephen A. Harrison et al. Nature Communications
- Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
- (2020) K.J. Lucas et al. DIGESTIVE AND LIVER DISEASE
- Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease
- (2020) James M. Paik et al. HEPATOLOGY
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease
- (2020) Hong Zhang et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Bile Acid Sequestration Reverses Liver Injury and Prevents Progression of NASH in Western Diet-Fed Mice
- (2020) Shogo Takahashi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
- (2020) Jiyu Zhou et al. Nature Communications
- Deoxycholic Acid-Induced Gut Dysbiosis Disrupts Bile Acid Enterohepatic Circulation and Promotes Intestinal Inflammation
- (2020) Mengque Xu et al. DIGESTIVE DISEASES AND SCIENCES
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content
- (2020) Yusuke Sasaki et al. Scientific Reports
- Bile acid-based therapies for non-alcoholic steatohepatitis and alcoholic liver disease
- (2020) Tiangang Li et al. Hepatobiliary Surgery and Nutrition
- Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)
- (2020) Stefano Fiorucci et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
- (2020) Stephen A. Harrison et al. GASTROENTEROLOGY
- Qiang-Gan formula extract improves non-alcoholic steatohepatitis via regulating bile acid metabolism and gut microbiota in mice
- (2020) Qiong Li et al. JOURNAL OF ETHNOPHARMACOLOGY
- Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease
- (2020) Stefan Traussnigg et al. WIENER KLINISCHE WOCHENSCHRIFT
- Hyocholic acid species improve glucose homeostasis through a distinct TGR5 and FXR signaling mechanism
- (2020) Xiaojiao Zheng et al. Cell Metabolism
- Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)
- (2020) Xuan G. Luong et al. PLoS One
- Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting
- (2020) Chad N. Brocker et al. Nature Communications
- Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression
- (2020) Nisreen Nimer et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice
- (2019) Patricia D. Finn et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- The traditional Chinese formulae Ling-gui-zhu-gan decoction alleviated non-alcoholic fatty liver disease via inhibiting PPP1R3C mediated molecules
- (2019) Yanqi Dang et al. BMC Complementary and Alternative Medicine
- Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters
- (2019) Lulu Sun et al. Acta Pharmaceutica Sinica B
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- SAT-357-Tropifexor, a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis: Interim results based on baseline body mass index from first two parts of Phase 2b study FLIGHT-FXR
- (2019) Arun Sanyal et al. JOURNAL OF HEPATOLOGY
- Microbiome Signatures Associated with Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease
- (2019) Jeffrey B. Schwimmer et al. GASTROENTEROLOGY
- Direct and Indirect Effects of FGF15 and FGF19 on Liver Fibrosis Development
- (2019) J D Schumacher et al. HEPATOLOGY
- Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial
- (2019) Stefan Traussnigg et al. Lancet Gastroenterology & Hepatology
- The loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity
- (2019) David E. Stec et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
- (2019) Vlad Ratziu et al. Contemporary Clinical Trials
- Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists
- (2019) Rohit A. Sinha et al. THYROID
- Hepatocyte peroxisome proliferator-activated receptor α regulates bile acid synthesis and transport
- (2019) Cen Xie et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Regulations of bile acid metabolism in mouse models with hydrophobic bile acid composition
- (2019) Akira Honda et al. JOURNAL OF LIPID RESEARCH
- Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism
- (2019) Fengjie Huang et al. Nature Communications
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Farnesoid X receptor activation induces the degradation of hepatotoxic 1‐deoxysphingolipids in non‐alcoholic fatty liver disease
- (2019) Zhibo Gai et al. LIVER INTERNATIONAL
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non–Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers
- (2019) Michael K. Badman et al. Clinical Pharmacology in Drug Development
- Bile Acid Metabolism in Liver Pathobiology
- (2018) John Y. L. Chiang et al. GENE EXPRESSION
- Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism
- (2018) Preeti Pathak et al. HEPATOLOGY
- The Nuclear Bile Acid Receptor FXR is a PKA- and FOXA2-Sensitive Activator of Fasting Hepatic Gluconeogenesis
- (2018) Maheul Ploton et al. JOURNAL OF HEPATOLOGY
- Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation
- (2018) Zhibo Gai et al. MOLECULAR PHARMACOLOGY
- Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand
- (2018) Adriana Carino et al. PHARMACOLOGICAL RESEARCH
- INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
- (2018) Jonathan D Roth et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
- (2018) Ying-Bin Hu et al. Drug Design Development and Therapy
- Angiopoietin-Like Protein 8 Is a Novel Vitamin D Receptor Target Gene Involved in Non-Alcoholic Fatty Liver Pathogenesis
- (2018) Carmelo García-Monzón et al. AMERICAN JOURNAL OF PATHOLOGY
- Association of non-alcoholic fatty liver disease with thyroid function: A systematic review and meta-analysis
- (2018) Zeqi Guo et al. DIGESTIVE AND LIVER DISEASE
- Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease
- (2018) Huikuan Chu et al. GUT
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- Extrahepatic PPARα modulates fatty acid oxidation and attenuates fasting-induced hepatosteatosis in mice
- (2018) Chad N. Brocker et al. JOURNAL OF LIPID RESEARCH
- Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD
- (2018) Cyrielle Caussy et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Molecular pathways of nonalcoholic fatty liver disease development and progression
- (2018) Fernando Bessone et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Gut microbiota and intestinal FXR mediate the clinical benefits of metformin
- (2018) Lulu Sun et al. NATURE MEDICINE
- Reduced expression of thyroid hormone receptor β in human nonalcoholic steatohepatitis
- (2018) Christin Krause et al. Endocrine Connections
- Noncanonical farnesoid X receptor signaling inhibits apoptosis and impedes liver fibrosis
- (2018) Hong Wang et al. EBioMedicine
- From pathogenesis to novel therapies in the treatment of primary biliary cholangitis
- (2017) Vincenzo Ronca et al. Expert Review of Clinical Immunology
- Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
- (2017) Na Jiao et al. GUT
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- (2017) Naga Chalasani et al. HEPATOLOGY
- Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
- (2017) Chris Estes et al. HEPATOLOGY
- Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice
- (2017) Kang Ho Kim et al. HEPATOLOGY
- Small heterodimer partner deletion prevents hepatic steatosis and when combined with farnesoid X receptor loss protects against type 2 diabetes in mice
- (2017) Oludemilade Akinrotimi et al. HEPATOLOGY
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis
- (2017) Parambir S. Dulai et al. HEPATOLOGY
- The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids
- (2017) Puneet Puri et al. HEPATOLOGY
- Adipokines and Non-Alcoholic Fatty Liver Disease: Multiple Interactions
- (2017) et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism
- (2017) Preeti Pathak et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Activation of intestinal hypoxia-inducible factor 2α during obesity contributes to hepatic steatosis
- (2017) Cen Xie et al. NATURE MEDICINE
- Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
- (2017) Anna M. Diehl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolomic profiling distinction of human nonalcoholic fatty liver disease progression from a common rat model
- (2017) JianHua Han et al. Obesity
- Editor’s Highlight: Clofibrate Decreases Bile Acids in Livers of Male Mice by Increasing Biliary Bile Acid Excretion in a PPARα-Dependent Manner
- (2017) Youcai Zhang et al. TOXICOLOGICAL SCIENCES
- Preference of Conjugated Bile Acids over Unconjugated Bile Acids as Substrates for OATP1B1 and OATP1B3
- (2017) Takahiro Suga et al. PLoS One
- BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis
- (2017) Adriana Carino et al. Scientific Reports
- Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARα in primary human hepatocytes
- (2016) Benjamin A. Kandel et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer
- (2016) Angeles Duran et al. CANCER CELL
- The biology of the metabolic syndrome and aging
- (2016) Ligia J. Dominguez et al. CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE
- An Intestinal Farnesoid X Receptor–Ceramide Signaling Axis Modulates Hepatic Gluconeogenesis in Mice
- (2016) Cen Xie et al. DIABETES
- Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin
- (2016) D. J. Nunez et al. DIABETES OBESITY & METABOLISM
- An Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
- (2016) Frank J. Gonzalez et al. GASTROENTEROLOGY
- G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice
- (2016) Ajay C. Donepudi et al. HEPATOLOGY
- Vertical sleeve gastrectomy activates GPBAR-1/TGR5 to sustain weight loss, improve fatty liver, and remit insulin resistance in mice
- (2016) Lili Ding et al. HEPATOLOGY
- Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis
- (2016) Milica Bozic et al. JOURNAL OF HEPATOLOGY
- Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans
- (2016) Shogo Takahashi et al. JOURNAL OF LIPID RESEARCH
- Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet–fed mice
- (2016) Anuradha Rao et al. Science Translational Medicine
- FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
- (2016) Len Verbeke et al. Scientific Reports
- Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
- (2016) Marialena Mouzaki et al. PLoS One
- Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis
- (2015) Brian C. Ferslew et al. DIGESTIVE DISEASES AND SCIENCES
- TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro
- (2015) Maria Reich et al. GUT
- Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
- (2015) Michal Pawlak et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
- (2015) Sungsoon Fang et al. NATURE MEDICINE
- Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells
- (2015) Mohamed-Sami Trabelsi et al. Nature Communications
- Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
- (2015) Changtao Jiang et al. Nature Communications
- Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential
- (2014) A. Brønden et al. DIABETES OBESITY & METABOLISM
- A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity
- (2014) D.-H. Kim et al. EMBO JOURNAL
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
- (2014) Changtao Jiang et al. JOURNAL OF CLINICAL INVESTIGATION
- Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans
- (2014) Ylva Bonde et al. JOURNAL OF LIPID RESEARCH
- G-Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5) Agonists Reduce the Production of Proinflammatory Cytokines and Stabilize the Alternative Macrophage Phenotype
- (2014) Klemens Högenauer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Modification on Ursodeoxycholic Acid (UDCA) Scaffold. Discovery of Bile Acid Derivatives As Selective Agonists of Cell-Surface G-Protein Coupled Bile Acid Receptor 1 (GP-BAR1)
- (2014) Valentina Sepe et al. JOURNAL OF MEDICINAL CHEMISTRY
- Thyroid hormone induction of human cholesterol 7 alpha-hydroxylase (Cyp7a1) in vitro
- (2014) Jan A. Lammel Lindemann et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Transcriptional regulation of autophagy by an FXR–CREB axis
- (2014) Sunmi Seok et al. NATURE
- Nutrient-sensing nuclear receptors coordinate autophagy
- (2014) Jae Man Lee et al. NATURE
- Microbiota Modification with Probiotics Induces Hepatic Bile Acid Synthesis via Downregulation of the Fxr-Fgf15 Axis in Mice
- (2014) Chiara Degirolamo et al. Cell Reports
- Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist
- (2013) Sama I. Sayin et al. Cell Metabolism
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis
- (2013) Jiesi Xu et al. HEPATOLOGY
- Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease
- (2013) Rachel H. McMahan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Retinoic Acid Receptor β Stimulates Hepatic Induction of Fibroblast Growth Factor 21 to Promote Fatty Acid Oxidation and Control Whole-body Energy Homeostasis in Mice
- (2013) Yu Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The involvement of endoplasmic reticulum stress in bile acid-induced hepatocellular injury
- (2013) Tetsuo Adachi et al. JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
- Genetic Variation inNR1H4Encoding the Bile Acid Receptor FXR Determines Fasting Glucose and Free Fatty Acid Levels in Humans
- (2013) Martin Heni et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Discovery of a Highly Potent, Nonabsorbable Apical Sodium-Dependent Bile Acid Transporter Inhibitor (GSK2330672) for Treatment of Type 2 Diabetes
- (2013) Yulin Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Farnesoid X Receptor Inhibits the Transcriptional Activity of Carbohydrate Response Element Binding Protein in Human Hepatocytes
- (2013) S. Caron et al. MOLECULAR AND CELLULAR BIOLOGY
- Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance
- (2013) Yongjie Ma et al. PHARMACEUTICAL RESEARCH
- Decreased hepatotoxic bile acid composition and altered synthesis in progressive human nonalcoholic fatty liver disease
- (2013) April D. Lake et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity
- (2013) Fei Li et al. Nature Communications
- Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
- (2012) Y. Yilmaz ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Thyroid Hormone Receptor Agonists Reduce Serum Cholesterol Independent of the LDL Receptor
- (2012) Jean Z. Lin et al. ENDOCRINOLOGY
- Activation of the Farnesoid X Receptor Induces Hepatic Expression and Secretion of Fibroblast Growth Factor 21
- (2012) Holly A. Cyphert et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Loss of FXR Protects against Diet-Induced Obesity and Accelerates Liver Carcinogenesis inob/obMice
- (2012) Yanqiao Zhang et al. MOLECULAR ENDOCRINOLOGY
- VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation
- (2012) Andrea Mencarelli et al. PLoS One
- Identification of Tetrahydropyrido[4,3-d]pyrimidine Amides as a New Class of Orally Bioavailable TGR5 Agonists
- (2012) David W. Piotrowski et al. ACS Medicinal Chemistry Letters
- Physical Activity Recommendations, Exercise Intensity, and Histological Severity of Nonalcoholic Fatty Liver Disease
- (2011) Kristin D Kistler et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Fibroblast Growth Factor 19 Treatment Ameliorates Disruption of Hepatic Lipid Metabolism in Farnesoid X Receptor (Fxr)-Null Mice
- (2011) Masaaki Miyata et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway
- (2011) Matthew J. Potthoff et al. Cell Metabolism
- Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity
- (2011) J. Prawitt et al. DIABETES
- Bile Acid Is a Host Factor That Regulates the Composition of the Cecal Microbiota in Rats
- (2011) K.B.M. Saiful Islam et al. GASTROENTEROLOGY
- SHP-dependent and -independent induction of peroxisome proliferator-activated receptor-γ by the bile acid sensor farnesoid X receptor counter-regulates the pro-inflammatory phenotype of liver myofibroblasts
- (2011) Barbara Renga et al. INFLAMMATION RESEARCH
- Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure
- (2011) Mitsuhiro Watanabe et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Dissociation of diabetes and obesity in mice lacking orphan nuclear receptor small heterodimer partner
- (2011) Young Joo Park et al. JOURNAL OF LIPID RESEARCH
- Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis
- (2010) N. Beraza et al. GUT
- High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial
- (2010) Ulrich F. H. Leuschner et al. HEPATOLOGY
- Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
- (2010) Herbert Tilg et al. HEPATOLOGY
- A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
- (2010) Vlad Ratziu et al. JOURNAL OF HEPATOLOGY
- Plasma metabolomic profile in nonalcoholic fatty liver disease
- (2010) Satish C. Kalhan et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
- (2010) G. Rizzo et al. MOLECULAR PHARMACOLOGY
- Hepatocyte Death: A Clear and Present Danger
- (2010) Harmeet Malhi et al. PHYSIOLOGICAL REVIEWS
- Systemic gut microbial modulation of bile acid metabolism in host tissue compartments
- (2010) J. R. Swann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
- (2009) Charles Thomas et al. Cell Metabolism
- Bile acid levels are increased in the liver of patients with steatohepatitis
- (2009) Márcia M. Aranha et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis
- (2009) A. Mencarelli et al. JOURNAL OF IMMUNOLOGY
- Bile acids: regulation of apoptosis by ursodeoxycholic acid
- (2009) Joana D. Amaral et al. JOURNAL OF LIPID RESEARCH
- Bile acid transporters
- (2009) Paul A. Dawson et al. JOURNAL OF LIPID RESEARCH
- Bile salts of vertebrates: structural variation and possible evolutionary significance
- (2009) Alan F. Hofmann et al. JOURNAL OF LIPID RESEARCH
- Mechanism of Vitamin D Receptor Inhibition of Cholesterol 7 -Hydroxylase Gene Transcription in Human Hepatocytes
- (2008) S. Han et al. DRUG METABOLISM AND DISPOSITION
- Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7α-hydroxylase gene expression
- (2008) Kwang-Hoon Song et al. HEPATOLOGY
- Mutations in the small heterodimer partner gene increase morbidity risk in Japanese type 2 diabetes patients
- (2008) Mayumi Enya et al. HUMAN MUTATION
- The organic solute transporter - , Ost -Ost , is essential for intestinal bile acid transport and homeostasis
- (2008) A. Rao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started